INVA · Innoviva, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $97.99M | - | $107.80M | $100.28M | $88.63M | - | $89.51M | $99.90M | $77.50M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $75.83M | - | $75.54M | $84.99M | $60.09M | - | - | - | - | - |
| R&D | $5.24M | - | $13.67M | $7.98M | $4.40M | - | $3.55M | $2.56M | $3.88M | - |
| SG&A | $32.44M | - | $27.29M | $26.41M | $27.49M | - | $26.22M | $27.74M | $30.41M | - |
| Total Operating Expenses | $37.68M | - | $40.96M | $30.30M | $34.28M | - | $82.66M | $139.18M | $32.38M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $38.15M | - | $43.24M | $54.69M | $25.80M | - | $6.85M | ($39.28M) | $45.12M | - |
| Interest Expense | $5.44M | - | $4.01M | $4.66M | $4.71M | - | $5.81M | $5.80M | $5.85M | - |
| Income Tax | $47.97M | - | $7.91M | $8.91M | $8.00M | - | $5.64M | ($4.59M) | $8.59M | - |
| Net Income | $186.59M | - | $89.91M | $63.69M | ($46.58M) | - | $1.21M | ($34.69M) | $36.53M | - |
| EPS - Basic | $2.52 | - | $1.30 | $1.01 | ($0.74) | - | $0.02 | ($0.55) | $0.58 | - |
| EPS - Diluted | $2.22 | - | $1.08 | $0.77 | ($0.74) | - | $0.02 | ($0.55) | $0.46 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $603.09M | $550.94M | $476.51M | $397.53M | $319.09M | $304.96M | $260.63M | $217.00M | $178.36M | $193.51M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $38.84M | $39.17M | $38.36M | $49.00M | $41.48M | $33.73M | $34.24M | $36.66M | $37.44M | $40.74M |
| Accounts Payable | $6.52M | $4.97M | $6.24M | $5.38M | $4.70M | $2.13M | $4.17M | $2.04M | $890.0K | $6.72M |
| Current Assets | $772.62M | $727.51M | $684.57M | $651.78M | $582.02M | $554.31M | $400.62M | $358.28M | $311.34M | $344.22M |
| Total Assets | $1.84B | $1.64B | $1.43B | $1.33B | $1.25B | $1.30B | $1.23B | $1.22B | $1.27B | $1.24B |
| Current Liabilities | $36.56M | $49.70M | $48.47M | $246.56M | $234.75M | $236.08M | $223.75M | $28.21M | $29.88M | $38.13M |
| Long-term Debt | $258.10M | $257.73M | $257.38M | $257.02M | $256.67M | $256.32M | $255.97M | $447.28M | $446.76M | $446.23M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $1.34B | $1.17B | $1.01B | $714.82M | $646.90M | $691.16M | $668.54M | $665.51M | $703.68M | $674.96M |
| Retained Earnings | $455.96M | $269.37M | $105.22M | $15.31M | ($48.38M) | ($1.80M) | ($22.13M) | ($23.34M) | $11.34M | ($25.19M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $35.28M | - | - | - | $48.62M | - | - | - | $37.05M | - |
| Investing Cash Flow | $37.01M | - | - | - | ($34.67M) | - | - | - | ($43.04M) | - |
| Financing Cash Flow | ($20.15M) | - | - | - | $183.0K | - | - | - | ($9.16M) | - |
| CapEx | $0 | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | $35.28M | - | - | - | - | - | - | - | $37.05M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 77.4% | - | 70.1% | 84.7% | 67.8% | - | - | - | - | - |
| Operating margin | 38.9% | - | 40.1% | 54.5% | 29.1% | - | 7.7% | -39.3% | 58.2% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | 190.4% | - | 83.4% | 63.5% | -52.6% | - | 1.4% | -34.7% | 47.1% | - |
| Free cash flow margin | 36.0% | - | - | - | - | - | - | - | 47.8% | - |
| FCF / Net income | 0.19 | - | - | - | - | - | - | - | 1.01 | - |
| R&D / Revenue | 5.3% | - | 12.7% | 8.0% | 5.0% | - | 4.0% | 2.6% | 5.0% | - |
| SG&A / Revenue | 33.1% | - | 25.3% | 26.3% | 31.0% | - | 29.3% | 27.8% | 39.2% | - |
| Effective tax rate | 20.4% | - | 8.1% | 12.3% | - | - | 82.3% | - | 19.0% | - |
| Return on assets | 10.2% | - | 6.3% | 4.8% | -3.7% | - | 0.1% | -2.8% | 2.9% | - |
| Return on equity | 13.9% | - | 8.9% | 8.9% | -7.2% | - | 0.2% | -5.2% | 5.2% | - |
| Return on invested capital | 1.9% | - | 3.1% | 4.9% | 2.3% | - | 0.4% | -2.8% | 3.2% | - |
| Liquidity | ||||||||||
| Current ratio | 21.13 | 14.64 | 14.12 | 2.64 | 2.48 | 2.35 | 1.79 | 12.70 | 10.42 | 9.03 |
| Quick ratio | 20.07 | 13.85 | 13.33 | 2.44 | 2.30 | 2.21 | 1.64 | 11.40 | 9.17 | 7.96 |
| Cash ratio | 16.50 | 11.09 | 9.83 | 1.61 | 1.36 | 1.29 | 1.16 | 7.69 | 5.97 | 5.07 |
| Leverage | ||||||||||
| Debt / Equity | 0.19 | 0.22 | 0.25 | 0.36 | 0.40 | 0.37 | 0.38 | 0.67 | 0.63 | 0.66 |
| Debt / Assets | 0.14 | 0.16 | 0.18 | 0.19 | 0.20 | 0.20 | 0.21 | 0.37 | 0.35 | 0.36 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 7.0x | - | 10.8x | 11.7x | 5.5x | - | 1.2x | -6.8x | 7.7x | - |
| Equity multiplier | 1.37 | 1.39 | 1.42 | 1.87 | 1.94 | 1.88 | 1.84 | 1.84 | 1.80 | 1.84 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.05 | - | 0.08 | 0.08 | 0.07 | - | 0.07 | 0.08 | 0.06 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 10.5x | - | 16.9x | 26.1x | - | - | 965.5x | - | 33.1x | - |
| P / B | 1.5x | - | 1.5x | 2.4x | 1.8x | - | 1.8x | 1.5x | 1.8x | - |
| P / S | 20.2x | - | 14.4x | 16.9x | 12.8x | - | 13.6x | 10.3x | 16.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 10.6% | - | 20.4% | 0.4% | 14.4% | - | 33.1% | 23.3% | 1.5% | - |
| Revenue CAGR (3y) | 8.7% | - | 17.0% | -2.5% | -0.5% | - | -2.9% | -0.3% | -3.2% | - |
| Revenue CAGR (5y) | 2.8% | - | 4.0% | 4.9% | 2.4% | - | 6.4% | 9.3% | 7.0% | - |
| Gross profit growth (YoY) | 26.2% | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 47.9% | - | 531.3% | - | -42.8% | - | -92.0% | - | 9.7% | - |
| Net income growth (YoY) | - | - | 7312.0% | - | - | - | -98.5% | - | 4.8% | - |
| EPS growth (YoY) | - | - | 5300.0% | - | - | - | -98.0% | - | 9.5% | - |
| EPS CAGR (3y) | 74.2% | - | -27.2% | 148.8% | - | - | -71.9% | - | -18.2% | - |
| EPS CAGR (5y) | 21.5% | - | 33.0% | 2.2% | - | - | -43.9% | - | 8.2% | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 44.4% | - |
| FCF CAGR (5y) | -15.9% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 107.4% | 69.7% | 51.1% | 7.4% | -8.1% | 2.4% | 6.5% | 19.9% | 25.3% | 19.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$586.16M totalRoyalty$236.48M · 40.3%
Product$172.13M · 29.4%
Xacduro$74.39M · 12.7%
Giapreza$73.61M · 12.6%
Xerava$23.52M · 4.0%
License And Other Revenue$2.72M · 0.5%
Cost Reimbursement$2.70M · 0.5%
ZEVTERA$610.0K · 0.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Innoviva against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Sep 8, 2015 | $0.2500 |
| Jun 10, 2015 | $0.2500 |
| Mar 10, 2015 | $0.2500 |
| Nov 21, 2014 | $0.2500 |
| Aug 26, 2014 | $0.2500 |